

**Artificial Intelligence (AI) in Pharmaceuticals: Global Markets**

Market Research Report | 2025-09-23 | 139 pages | BCC Research

**AVAILABLE LICENSES:**

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

**Report description:**

## Description

## Report Scope

This report on the global market for AI in pharmaceuticals explores market dynamics and trends, and analyzes technological developments, software performance, clinical trials, new product approvals and emerging technologies. The report also includes profiles of leading companies and their strategies.

The report explores how AI is transforming the pharmaceutical industry through enhanced diagnostic capabilities, early disease detection, clinical trial optimization, drug discovery and personalized treatment planning. It also examines AI disruption across industry verticals and value chain stages, while presenting market spending patterns, investment forecasts, R&D expenditures and venture capital funding. The report segments the market by product type, application and region. Types include software and services. Applications include drug discovery and development, clinical trials, personalized medicines and others. The four regions covered are North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data has been provided for 2024 as the base year, with forecasts for 2025 through 2030.

## Report Includes

- 27 data tables and 62 additional tables
- An analysis of the global markets for artificial intelligence (AI) in the pharmaceuticals industry
- Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
- Estimates of the market's size and revenue growth prospects, accompanied by a market share analysis by product type, application and region
- Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
- Insights derived from Porter's Five Forces model, as well as a global supply chain analysis
- Case studies on AI implementation to streamline processes across drug discovery and development, manufacturing, quality

control and patient care

- A relevant patent analysis, featuring key granted and published patents
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Google DeepMind, Atomwise Inc., Insilico Medicine, Recursion Pharmaceuticals and Nvidia Corp.

## Executive Summary

### Summary:

The global market for artificial intelligence (AI) in pharmaceuticals is estimated to grow from \$3.8 billion in 2025 to reach \$15.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 31.7% from 2025 through 2030.

In the pharmaceutical industry, AI is no longer a futuristic concept but a strategic imperative, transforming everything from early-stage drug discovery, where it drastically accelerates target identification and molecule design, to optimizing clinical trials by enhancing patient recruitment and predicting outcomes. Beyond R&D, AI is streamlining manufacturing processes through predictive maintenance and quality control (QC), and revolutionizing supply chain management with accurate demand forecasting and real-time inventory optimization, ultimately leading to faster time-to-market, reduced costs, and the promise of more personalized therapies for patients. While challenges remain in data integration, regulatory frameworks and expertise acquisition, the demonstrable benefits and expanding use cases underscore a qualitative market trend toward AI as a foundational technology for innovation and competitive advantage in pharma.

### Table of Contents:

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Market Dynamics and Growth Factors

Emerging Technologies

Segmental Analysis

Regional Analysis

Conclusion

Chapter 2 Market Overview

Current Market Overview

Macroeconomic Factors Analysis

Government Policy and Regulation

Technological Infrastructure and Digital Readiness

Global Trade and Supply Chain Dynamics

Impact of U.S. Tariffs

Porter's Five Forces Analysis

Potential for New Entrants (Moderate to High)

Bargaining Power of Suppliers (Low to Moderate)

Bargaining Power of Buyers (High)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

Threat of Substitute Products or Services (Low to Moderate)  
Industry Level of Competitiveness (High)  
AI's Impact on the Pharmaceutical Value Chain  
Drug Discovery and Preclinical Development: Accelerated Innovation  
Clinical Trials: Smarter Design and Execution  
Manufacturing and Supply Chain: Intelligent Operations  
Regulatory Affairs and Compliance: Automation and Accuracy  
Commercialization and Market Access: Data-Driven Strategies  
Post-Market Surveillance: Continuous Learning and Safety Monitoring  
Use Cases  
Use Case 1: Generative AI for Efficiency in Regulatory Submissions  
Use Case 2: Generative AI-Enabled R&D Assistant for Synthesis Routes

Chapter 3 Market Dynamics  
Market Dynamics  
Market Drivers  
Faster Drug Discovery and Development  
Increasing Adoption of AI in Clinical Trials  
Demand for Precision Medicine and AI Applications  
Market Restraints  
Regulatory and Ethical Concerns  
Data Challenges  
Market Opportunities  
Collaborations and Investments  
Increased Focus on Drug Discovery in Emerging Nations  
Advances of Generative AI in Molecular Design

Chapter 4 Regulatory Landscape  
Overview  
Regulatory Scenario in the U.S.  
Regulatory Scenario in Europe  
Regulatory Scenario in Japan  
Regulatory Scenario in China  
Other Countries

Chapter 5 Emerging Trends and Pipeline Analysis  
Emerging Trends  
Generative AI in Pharma  
Federated Learning  
Natural Language Processing  
Generative Adversarial Networks  
Pipeline Analysis  
Takeaways  
Patent Analysis  
Findings

Chapter 6 Market Segment Analysis  
Segmentation Breakdown  
Market Breakdown, by Product Type  
Takeaways  
Software

Services

Market Breakdown, by Application

Takeaways

Drug Discovery and Development

Clinical Trials

Personalized Medicine

Other Applications

Geographic Breakdown

Market Breakdown, by Region

Takeaways

North America

Europe

Asia-Pacific

Rest of the World (RoW)

Chapter 7 Competitive Intelligence

Takeaways

Competitive Analysis

Strategic Analysis

Investment Landscape

Chapter 8 Sustainability in AI in the Pharmaceutical Industry: ESG Perspective

Introduction to ESG

Sustainability Trends and Initiatives

ESG Risk Ratings

Concluding Remarks from BCC Research

Chapter 9 Appendix

Research Methodology

Sources

Abbreviations

Company Profiles

AICURE

ATOMWISE INC.

BENEVOLENTAI

GOOGLE DEEPMIND

HEALX

IKTOS

INSILICO MEDICINE

INVENIAI LLC.

NVIDIA CORP.

PATHAI INC.

RECURSION

SCHRODINGER INC.

SYREN CLOUD INC.

TEMPUS AI INC.

XTALPI INC.

Emerging Start-ups/Market Disruptors

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Artificial Intelligence (AI) in Pharmaceuticals: Global Markets**

Market Research Report | 2025-09-23 | 139 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>	EU Vat / Tax ID / NIP number*	
Company Name*	<input type="text"/>	<input type="text"/>	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-08"/>

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)